How is sandostatin administered for carcinoid syndrome?

How is sandostatin usually given for carcinoid syndrome?

Sandostatin is given either as a subcutaneous injection three times a day or as a long-acting intramuscular injection once every four weeks. Subcutaneous dosing starts at 50 mcg two or three times daily and can be raised to 100–600 mcg per day in divided doses. The long-acting form is started after the patient has tolerated the short-acting version for at least two weeks; the usual dose is 20 mg every four weeks, with possible adjustments to 10 mg or 30 mg based on symptom control.

What determines whether a patient receives daily or monthly dosing?

Daily subcutaneous injections are used when rapid onset or dose titration is needed, for example during acute flare-ups or when starting therapy. Once symptoms stabilize, most patients switch to the monthly intramuscular depot formulation for convenience and steady drug levels. The choice also depends on patient dexterity, travel, and cost considerations.

How long does it take for symptom relief to appear?

Short-acting Sandostatin can reduce flushing and diarrhea within hours. Full effect on hormone levels usually appears within one to two weeks. The long-acting version reaches steady state after two to three injections, so symptom improvement may take four to eight weeks.

Can the dose be adjusted if symptoms return?

Yes. If flushing or diarrhea worsen, clinicians may increase the monthly dose by 10 mg increments or add supplemental short-acting injections for breakthrough symptoms. Blood tests for chromogranin A and 5-HIAA help guide adjustments.

What side effects do patients most often report?

Injection-site pain, nausea, abdominal cramps, and loose stools are common in the first weeks. Gallstones, elevated blood sugar, and slowed heart rate can develop with long-term use, so periodic ultrasound and glucose monitoring are recommended.

When does the patent for Sandostatin expire?

The original U.S. patent for octreotide expired years ago, but the long-acting Sandostatin LAR formulation remains under patent protection until 2024. After expiry, generic and biosimilar versions are expected to enter the market.

Who manufactures the long-acting version?

Novartis manufactures both the short-acting and long-acting Sandostatin products. Several generic manufacturers now supply the daily subcutaneous form.

Are there alternatives if monthly injections are not tolerated?

Lanreotide (Somatuline Depot) is given as a deep subcutaneous injection every four weeks and offers a similar profile. Oral octreotide (Mycapssa) is also available for select patients who prefer capsules over injections.

[1] https://www.drugpatentwatch.com/drug/octreotide
[2] https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/019667s043,020386s025lbl.pdf